Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation - Hanf, Dorothea; Heining, Christoph; Laaber, Karin; Nebelung, Heiner; Uhrig, Sebastian; Hutter, Barbara; Jahn, Arne; Richter, Daniela; Aust, Daniela; Herbst, Friederike; Fröhling, Stefan; Glimm, Hanno; et al. (JCO precision oncology, 2021)
Im Text ist "G623R" hochgestellt